Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675204 | 1.00 | HPGD (0.34) | HPGDKMT2ASMN1; SMN2HTR2AHTR2C | |
| SCHEMBL22738090 | 0.90 | HRH3 (0.39) | HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL24033707 | 0.87 | HTR6 (0.44) | — | |
| SCHEMBL20712929 | 0.87 | HTR6 (0.44) | — | |
| SCHEMBL2371666 | 0.86 | KMT2A (0.36) | HPGDKMT2ASMN1; SMN2HTR2AHTR2C | |
| SCHEMBL993342 | 0.86 | MEN1 (0.31) | KMT2A | |
| Hydrochloric Acid SCHEMBL34473706 | 0.85 | HTR6 (0.42) | — | |
| Hydrochloric Acid SCHEMBL29134756 | 0.85 | HTR6 (0.42) | — | |
| Trifluoroacetic Acid SCHEMBL3335481 | 0.84 | DPP4 (0.35) | — | |
| Trifluoroacetic Acid SCHEMBL3335491 | 0.84 | DPP4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102459272-B | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH INC | 2014-08-06 | — | — | CN | disclosed |
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2011119704-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2010138589-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | HPGD 3243/4885KMT2A 4323/4885SMN1; SMN2 2134/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | HPGD 3173/4885KMT2A 4343/4885SMN1; SMN2 2248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.